Novavax, Inc. (NASDAQ:NVAX) Receives $17.83 Average PT from Analysts

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has been assigned an average rating of "Hold" from the six ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $17.83.

A number of analysts have recently issued reports on NVAX shares. B. Riley restated a "buy" rating and issued a $26.00 target price (up previously from $23.00) on shares of Novavax in a report on Thursday, October 10th. Jefferies Financial Group decreased their price objective on Novavax from $31.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday, October 16th. Finally, HC Wainwright reiterated a "buy" rating and issued a $19.00 target price on shares of Novavax in a report on Tuesday, December 10th.

Novavax Trading Up 5.9 %

NASDAQ:NVAX traded up $0.50 during midday trading on Friday, hitting $8.90. 2,283,020 shares of the stock were exchanged, compared to its average volume of 5,372,834. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -3.93 and a beta of 2.07. Novavax has a one year low of $3.53 and a one year high of $23.86. The business has a 50-day moving average price of $8.62 and a two-hundred day moving average price of $10.99.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. During the same quarter last year, the firm posted ($1.26) earnings per share. Novavax's revenue was down 54.8% compared to the same quarter last year. Sell-side analysts forecast that Novavax will post -1.31 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Rachel K. King sold 4,150 shares of the firm's stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the transaction, the director now owns 14,770 shares of the company's stock, valued at approximately $133,225.40. This trade represents a 21.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James F. Young sold 4,600 shares of the firm's stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the transaction, the director now directly owns 57,160 shares in the company, valued at approximately $484,716.80. The trade was a 7.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock worth $119,641 in the last 90 days. Corporate insiders own 1.00% of the company's stock.

Hedge Funds Weigh In On Novavax

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank lifted its position in Novavax by 26.9% in the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company's stock valued at $62,000 after acquiring an additional 1,036 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Novavax by 38.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 1,598 shares in the last quarter. US Bancorp DE boosted its position in shares of Novavax by 3,538.8% during the third quarter. US Bancorp DE now owns 12,299 shares of the biopharmaceutical company's stock worth $155,000 after buying an additional 11,961 shares during the period. Entropy Technologies LP bought a new position in shares of Novavax during the third quarter worth about $158,000. Finally, Algert Global LLC acquired a new stake in Novavax in the 2nd quarter valued at approximately $161,000. 53.04% of the stock is owned by institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.